I'm not expecting a change course this close to BLA submission. Really, the only decision we have at this point is sell if we don't think they will get the job done using the current path or hold otherwise. Biotech is the haves and the have nots, cydy is a have not. Many pre-revenue biotechs are in the same situation and BP is use to winning, but cydy is close to the finish line. So, I believe cydy will get there even if they have to limp across the line without BP. Using the current path, it seems they will be able to make it.

Quote:

---

I have ZERO idea what kind of experience NP has with deals like this. Has he surrounded himself with people who DO have great experience navigating such deals? I don't know.

---

Do you know who they brought in to do these negotiations?